Paraoxonase2 C311S polymorphism and low levels of HDL contribute to a higher mortality risk after acute myocardial infarction in elderly patients

Molecular Genetics and Metabolism

Volumn 98, Issue 3, 2009, Pages 314-318

  Marchegiani, Francesca ^a   Spazzafumo, Liana ^a   Provinciali, Mauro ^a   Cardelli, Maurizio ^a   Olivieri, Fabiola ^b   Franceschi, Claudio ^c   Lattanzio, Fabrizia ^a   Antonicelli, Roberto ^a  

^a INRCA   (Italy)

^b UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^c UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Acute myocardial infarction; Elderly; Genetics; Paraoxonase2; Polymorphism

Indexed keywords

ARYLDIALKYLPHOSPHATASE 2; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TROPONIN T;

ACUTE HEART INFARCTION; AGED; ALLELE; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; ENZYME POLYMORPHISM; FEMALE; FOLLOW UP; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HEART INJURY; HEART MUSCLE ISCHEMIA; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOGENESIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS;

AGED; AGED, 80 AND OVER; ARYLDIALKYLPHOSPHATASE; CHOLESTEROL, HDL; FEMALE; GENOTYPE; HUMANS; MALE; MYOCARDIAL INFARCTION; POLYMORPHISM, GENETIC; RISK FACTORS;

EID: 70349728399     PISSN: 10967192     EISSN: 10967206     Source Type: Journal    
DOI: 10.1016/j.ymgme.2009.05.008     Document Type: Article

References (31)

1. Klimov A.N., Gurevich V.S., Nikiforova A.A., Shatilina L.V., Kuzmin A.A., Plavinsky S.L., and Teryukova N.P. Antioxidative activity of high density lipoproteins in vivo. Atherosclerosis 100 (1993) 13-18
2. Mackness M.I., Arrol S., Abbott C., and Durrington P.N. Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. Atherosclerosis 104 (1993) 129-135
3. Primo-Parmo S.L., Sorenson R.C., Teiber J., and La Du B.N. The human serum paraoxonase/arylesterase gene (PON1) is one member of a multigene family. Genomics 33 (1996) 498-507
4. Rosenblat M., Gaidukov L., Khersonsky O., Vaya J., Oren R., Tawfik D.S., and Aviram M. The catalytic histidine dyad of high density lipoprotein-associated serum paraoxonase-1 (PON1) is essential for PON1-mediated inhibition of low density lipoprotein oxidation and stimulation of macrophage cholesterol efflux. J. Biol. Chem. 281 (2006) 7657-7665
5. Wheeler J.G., Keavney B.D., Watkins H., Collins R., and Danesh J. Four paraoxonase gene polymorphisms in 11212 cases of coronary hearth disease and 12786 controls: meta-analysis of 43 studies. Lancet 363 (2004) 689-695
6. Marchegiani F., Marra M., Olivieri F., Cardelli M., James R.W., Boemi M., and Franceschi C. Paraoxonase1: genetics and activities during aging. Rejuvenation Res. 11 (2008) 113-127
7. Marchegiani F., Marra M., Spazzafumo L., James R.W., Boemi M., Olivieri F., Cardelli M., Cavallone L., Bonfigli A.R., and Franceschi C. Paraoxonase activity and genotype predispose to successful aging. J. Gerontol. A Biol. Sci. Med. Sci. 61 (2006) 541-546
8. Rea I.M., McKeown P.P., McMaster D., Young I.S., Patterson C., Savage M.J., Belton C., Marchegiani F., Olivieri F., Bonafe M., and Franceschi C. Paraoxonase polymorphisms PON1 192 and 55 and longevity in Italian centenarians and Irish nonagenarians. A pooled analysis. Exp. Gerontol. 39 (2004) 629-635
9. Horke S., Witte I., Wilgenbus P., Krüger M., Strand D., and Förstermann U. Paraoxonase-2 reduces oxidative stress in vascular cells and decreases endoplasmic reticulum stress-induced caspase activation. Circulation 115 (2007) 2055-2064
10. Ng C.J., Wadleigh D.J., Gangopadhyay A., Hama S., Grijalva V.R., Navab M., Fogelman A.M., and Reddy S.T. Paraoxonase-2 is a ubiquitously expressed protein with antioxidant properties and is capable of preventing cell-mediated oxidative modification of low density lipoprotein. J. Biol. Chem. 276 (2001) 44444-44449
11. Ng C.J., Bourquard N., Grijalva V., Hama S., Shih D.M., Navab M., Fogelman A.M., Lusis A.J., Young S., and Reddy S.T. Paraoxonase-2 deficiency aggravates atherosclerosis in mice despite lower apolipoprotein-B-containing lipoproteins: anti-atherogenic role for paraoxonase-2. J. Biol. Chem. 281 (2006) 29491-29500
12. Mackness B., Quarck R., Verreth W., Mackness M., and Holvoet P. Human paraoxonase-1 overexpression inhibits atherosclerosis in a mouse model of metabolic syndrome. Arterioscler. Thromb. Vasc. Biol. 26 (2006) 1545-1550
13. Ng C.J., Hama S.Y., Bourquard N., Navab M., and Reddy S.T. Adenovirus mediated expression of human paraoxonase 2 protects against the development of atherosclerosis in apolipoprotein E-deficient mice. Mol. Genet. Metab. 89 (2006) 368-373
14. Ng C.J., Bourquard N., Hama S.Y., Shih D., Grijalva V.R., Navab M., Fogelman A.M., and Reddy S.T. Adenovirus-mediated expression of human paraoxonase 3 protects against the progression of atherosclerosis in apolipoprotein E-deficient mice. Arterioscler. Thromb. Vasc. Biol. 27 (2007) 1368-1374
15. Aviram M., and Rosenblat M. Paraoxonases 1, 2, and 3, oxidative stress, and macrophage foam cell formation during atherosclerosis development. Free Radic. Biol. Med. 37 (2004) 1304-1316
16. Mochizuki H., Scherer S.W., Xi T., Nickle D.C., Majer M., Huizenga J.J., Tsui L.C., and Prochazka M. Human PON2 gene at 7q21.3: cloning, multiple mRNA forms, and missense polymorphisms in the coding sequence. Gene 213 (1998) 149-157
17. Sanghera D.K., Aston C.E., Saha N., and Kamboh M.I. DNA polymorphisms in two paraoxonase genes (PON1 and PON2) are associated with the risk of coronary heart disease. Am. J. Hum. Genet. 62 (1998) 36-44
18. Imai Y., Morita H., Kurihara H., Sugiyama T., Kato N., Ebihara A., Hamada C., Kurihara Y., Shindo T., Oh-hashi Y., and Yazaki Y. Evidence for association between paraoxonase gene polymorphisms and atherosclerotic diseases. Atherosclerosis 149 (2000) 435-442
19. Chen Q., Reis S.E., Kammerer C.M., McNamara D.M., Holubkov R., Sharaf B.L., Sopko G., Pauly D.F., Merz C.N., and Kamboh M.I. WISE Study Group, Association between the severity of angiographic coronary artery disease and paraoxonase gene polymorphisms in the National Heart, Lung, and Blood Institute-sponsored Women's Ischemia Syndrome Evaluation (WISE) study. Am. J. Hum. Genet. 72 (2003) 13-22
20. Boright A.P., Connelly P.W., Brunt J.H., Scherer S.W., Tsui L.C., and Hegele R.A. Genetic variation in paraoxonase-1 and paraoxonase-2 is associated with variation in plasma lipoproteins in Alberta Hutterites. Atherosclerosis 139 (1998) 131-136
21. Leus F.R., Zwart M., Kastelein J.J., and Voorbij H.A. PON2 gene variants are associated with clinical manifestations of cardiovascular disease in familial hypercholesterolemia patients. Atherosclerosis 154 (2001) 641-649
22. Martinelli N., Girelli D., Olivieri O., Stranieri C., Trabetti E., Pizzolo F., Friso S., Tenuti I., Cheng S., Grow M.A., Pignatti P.F., and Corrocher R. Interaction between smoking and PON2 Ser311Cys polymorphism as a determinant of the risk of myocardial infarction. Eur. J. Clin. Invest. 34 (2004) 14-20
23. Bertrand M.E., Simoons M.L., Fox K.A., Wallentin L.C., Hamm C.W., McFadden E., De Feyter P.J., Specchia G., and Ruzyllo W. Task Force on the Management of Acute Coronary Syndromes of the European Society of Cardiology, Task Force on the Management of Acute Coronary Syndromes of the European Society of Cardiology Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur. Heart J. 23 (2002) 1809-1840
24. Guidelines Committee, European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension, J. Hypertens. 21 (2003) 1011-1053.
25. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus, Diabetes Care 20 (1997) 1183-1197.
26. Pearte C.A., Furberg C.D., O'Meara E.S., Psaty B.M., Kuller L., Powe N.R., and Manolio T. Characteristics and baseline clinical predictors of future fatal versus nonfatal coronary heart disease events in older adults: the Cardiovascular Health Study. Circulation 113 (2006) 2177-2185
27. Jalilian A., Javadi E., Akrami M., Fakhrzadeh H., Heshmat R., Rahmani M., and Bandarian F. Association of cys 311 ser polymorphism of paraoxonase-2 gene with the risk of coronary artery disease. Arch. Iran. Med. 11 (2008) 544-549
28. Mackness B., McElduff P., and Mackness M.I. The paraoxonase-2-310 polymorphism is associated with the presence of microvascular complications in diabetes mellitus. J. Intern. Med. 258 (2005) 363-368
29. Pinizzotto M., Castillo E., Fiaux M., Temler E., Gaillard R.C., and Ruiz J. Paraoxonase2 polymorphisms are associated with nephropathy in type II diabetes. Diabetologia 44 (2001) 104-107
30. Prochazka M., Thompson D.B., Knowler W.C., Bennet P.H., Bogardus C., Scherer S.W., and Tsui L.C. Linkage and association of markers at 7q21.3-22.1 with non-insulin-dependent diabetes mellitus (NIDDM) in Pima Indians. Cytogenet. Cell Genet. 71 (1995) 30
31. Antonicelli R., Olivieri F., Cavallone L., Spazzafumo L., Bonafè M., Marchegiani F., Cardelli M., Galeazzi R., Giovagnetti S., Perna G.P., and Franceschi C. Tumor necrosis factor-alpha gene -308G>A polymorphism is associated with ST-elevation myocardial infarction and with high plasma levels of biochemical ischemia markers. Coron. Artery Dis. 16 (2005) 489-493